Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million on July 3, 2023. Yinchuan Meihetai Pharmaceutical Chain Co., Ltd reported a Total assets worth CNY 150.05 million, Total Common equity worth CNY 9.43 million, EBIT of CNY 195.50 million and Net Income of CNY 16.95 million in year ending 2022. Transaction has already been approved by board of director's of Yinchuan Meihetai Pharmaceutical Chain Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.75 CNY | -0.61% | -3.37% | -25.17% |
1st Jan change | Capi. | |
---|---|---|
-25.17% | 28Cr | |
+21.11% | 7.29TCr | |
-4.38% | 2.35TCr | |
+4.16% | 850.79Cr | |
+9.26% | 841.57Cr | |
-24.53% | 756.14Cr | |
+13.31% | 522Cr | |
0.00% | 420.05Cr | |
-1.31% | 391.46Cr | |
+6.13% | 391.15Cr |
- Stock Market
- Equities
- 301126 Stock
- News Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd
- Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd agreed to acquire Yinchuan Meihetai Pharmaceutical Chain Co., Ltd. from Xie Huiyang and Xie Xiaolong for approximately CNY 250 million.